Bausch Health (Bausch Health) Days Sales Outstanding

: 74.77 (As of Dec. 2023)

View and export this data going back to 1994. Start your Free Trial

Bausch Health's average Accounts Receivable for the three months ended in Dec. 2023 was $1,973 Mil. Bausch Health's Revenue for the three months ended in Dec. 2023 was $2,408 Mil. Hence, Bausch Health's Days Sales Outstanding for the three months ended in Dec. 2023 was 74.77.

The historical rank and industry rank for Bausch Health's Days Sales Outstanding or its related term are showing as below:

BHC' s Days Sales Outstanding Range Over the Past 10 Years
Min: 72.56 Med: 79.41 Max: 99.59
Current: 76.56

During the past 13 years, Bausch Health's highest Days Sales Outstanding was 99.59. The lowest was 72.56. And the median was 79.41.

BHC's Days Sales Outstanding is ranked worse than
54.85% of 999 companies
in the Drug Manufacturers industry
Industry Median: 71.93 vs BHC: 76.56

Bausch Health's Days Sales Outstanding increased from Dec. 2022 (73.42) to Dec. 2023 (74.77).

Bausch Health Days Sales Outstanding Historical Data

The historical data trend for Bausch Health's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bausch Health Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

78.59

77.67

72.53

80.09

78.94

Bausch Health Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Days Sales Outstanding																73.42	81.63	72.24	75.25	74.77

Competitive Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Bausch Health's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bausch Health Days Sales Outstanding Distribution

For the Drug Manufacturers industry and Healthcare sector, Bausch Health's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Bausch Health's Days Sales Outstanding falls into.

Bausch Health Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Bausch Health's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (1790	+	1998)	/	2 )	/	8757	*	365
=	1894					/	8757	*	365
=	78.94

Bausch Health's Days Sales Outstanding for the quarter that ended in Dec. 2023 is calculated as:

	Days Sales Outstanding (Q: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Sep. 2023 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (1948	+	1998)	/	2 )	/	2408	*	365 / 4
=	1973					/	2408	*	365 / 4
=	74.77

Bausch Health (NYSE:BHC) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Bausch Health Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Bausch Health's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Bausch Health (Bausch Health) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bausch Health Companies Inc (NYSE:BHC) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

BVF:Germany BVF:Germany BHC:Canada

Address

2150 Saint Elzear Boulvard West, Laval, QC, CAN, H7L 4A8

Website

https://www.bauschhealth.com

Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the dermatology, gastrointestinal, and ophthalmology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.

Executives

Seana Carson	officer: EVP, General Counsel	400 SOMERSET CORPORATE BLVD, BRIDGEWATER NJ 08807
John S Barresi	officer: SVP, Controller & CAO	727 FIFTH AVENUE, NEW YORK NY 10022
Richard Mulligan	director	C/O ICAHN CAPITAL LP, 767 FIFTH AVENUE, SUITE 4700, NEW YORK NY 10153
Tom George Vadaketh	officer: EVP, Chief Financial Officer	1727 JOCKEYS WAY, YARDLEY PA 19067
Robert Spurr	director, officer: U.S. President-Pharma Business	C/O BAUSCH HEALTH COMPANIES INC., 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Joseph F Gordon	officer: Pres&Co-Head Bausch&Lomb/Int'l	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Frederick Munsch	officer: SVP, Controller and CAO	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Christina Ackermann	officer: EVP AND GENERAL COUNSEL	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Sam Eldessouky	officer: EVP & Chief Financial Officer	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Steven D Miller	director	16690 COLLINS AVENUE, PH, SUNNY ISLE BEACH FL 33160
Von Eschenbach Andrew C.	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
De Schutter Richard U	director	C/O BLCO, 400 SOMERSET CORPORATE BLVD., BRIDGEWATER NJ 08807
Brett Icahn	director	C/O ICAHN ENTERPRISES L.P., 16690 COLLINS AVE., PH, SUNNY ISLES FL 33160
William D. Humphries	officer: EVP, COMPANY GROUP CHAIRMAN	C/O STRATA SKIN SCIENCES, INC., 5 WALNUT GROVE DRIVE SUITE 140, HORSHAM PA 19044
Valueact Capital Master Fund, L.p.	director, other: See remarks	ONE LETTERMAN DRIVE, BUILDING D, 4TH FLOOR, SAN FRANCISCO CA 94129